TY - JOUR T1 - Neoantigen DNA vaccines are safe, feasible, and capable of inducing neoantigen-specific immune responses in patients with triple negative breast cancer JF - medRxiv DO - 10.1101/2021.11.19.21266466 SP - 2021.11.19.21266466 AU - Xiuli Zhang AU - S. Peter Goedegebuure AU - Nancy B. Myers AU - Tammi Vickery AU - Michael D. McLellan AU - Feng Gao AU - Mark A. Sturmoski AU - Michael Y. Chen AU - Samuel W. Kim AU - Ina Chen AU - Jesse T Davidson, 4th AU - Narendra V. Sankpal AU - Jasreet Hundal AU - Lijin Li AU - Stephanie Myles AU - Rama Suresh AU - Cynthia X. Ma AU - Ademuyiwa Foluso AU - Andrea Wang-Gillam AU - Sherri Davies AU - Ian Hagemann AU - Elaine R. Mardis AU - Malachi Griffith AU - Christopher A. Miller AU - Ted H. Hansen AU - Timothy P. Fleming AU - Robert D. Schreiber AU - William E. Gillanders Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/21/2021.11.19.21266466.abstract N2 - PURPOSE Cancer neoantigens are important targets of cancer immunotherapy. Neoantigen vaccines have the potential to induce or enhance highly specific antitumor immune responses with minimal risk of autoimmunity. We have developed a neoantigen DNA vaccine platform capable of efficiently presenting both HLA class I and II epitopes. To test the safety, feasibility and efficacy of this platform, we performed a phase 1 clinical trial in triple negative breast cancer patients with persistent disease following neoadjuvant chemotherapy, a patient population at high risk of disease recurrence.EXPERIMENTAL DESIGN Expressed somatic mutations were identified by tumor/normal exome sequencing and tumor RNA sequencing. The pVACtools software suite was used to identify and prioritize cancer neoantigens. Neoantigen DNA vaccines were designed and manufactured in an academic GMP facility at Washington University School of Medicine. Neoantigen DNA vaccines were administered via electroporation following completion of standard of care therapy. Safety was measured by clinical and laboratory evaluation. Immune responses were assessed by ELISPOT, flow cytometry and TCR sequencing.RESULTS 18 subjects received three doses of a personalized neoantigen DNA vaccine encoding on average 11 neoantigens per patient (range 4-20). The vaccinations were well tolerated with limited adverse events, primarily related to injection site reactions. Neoantigen-specific immune responses were induced in 16/18 patients as measured by ELISPOT and flow cytometry. At a median follow-up of 36 months, progression-free survival was 87.5% (95% CI: 72.7-100%) in the cohort of vaccinated patients compared to 49% (95% CI: 36.4-65.9%) in a cohort of institutional historical control patients (p=0.011).CONCLUSIONS Neoantigen DNA vaccines are safe, feasible, and capable of inducing a neoantigen-specific immune response. There is preliminary evidence of improved disease-free survival compared to historical controls.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02348320Funding StatementThis project was supported by grants from Susan G. Komen for the Cure (KG111025), the Alvin J. Siteman Cancer Center (Siteman Investment Program grant 4035), the National Institute of Health (NIH) grant R01 CA240983, the National Cancer Institute (NCI) Cancer Center Support Grant P30-CA091842, the NCI grant U01 CA248235, the NCI training grant T32 CA009621, the Foundation for Barnes-Jewish Hospital (to SPG), and the Centene Corporation contract (P19-00559) for the Washington University-Centene ARCH Personalized Medicine Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Washington University in St Louis School of Medicine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -